Rufinamide (Inovelon®) 40 mg/ml oral suspension
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000879
English
Authors' recommendations:
Rufinamide (Inovelon®) 40 mg/ml oral suspension is recommended as an option for use within NHS Wales as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 4 years of
age and older where other adjunctive treatments have proved sub-optimal or have not been tolerated.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/Documents/371/rufinamide%20%28Inovelon%29%20FAR.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Seizures
- Epilepsy
- Triazoles
- Anticonvulsants
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.